Table 2.
Origin of metastases.
| Organ | Number of Patients | ||
|---|---|---|---|
| Total | Pre-BMCB | Post-BMCB | |
| Lung | 37 | 2 | 35 |
| Kidney | 22 | 2 | 20 |
| Breast | 20 | 1 | 19 |
| Liver | 17 | 1 | 16 |
| Thyroid | 13 | 3 | 10 |
| Malignant lymphoma | 12 | 4 | 8 |
| Colon | 12 | 2 | 10 |
| Multiple myeloma | 11 | 0 | 11 |
| Sarcoma | 10 | 3 | 7 |
| Prostate | 9 | 1 | 8 |
| Esophagus | 4 | 0 | 4 |
| Bladder | 4 | 0 | 4 |
| Malignant melanoma | 4 | 0 | 4 |
| Ovary | 2 | 0 | 2 |
| Uterus | 2 | 0 | 2 |
| Pancreas | 2 | 0 | 2 |
| Other | 19 | 6 | 13 |
| Unknown | 26 | 8 | 18 |
| Total | 226 | 33 | 193 |
| Percent of unknown (%) | 11.5 | 24.2 | 9.3 |
Fisher’s exact test was used to identify the differences in unknown tumor rates between pre- and post-BMCB, p = 0.033. Abbreviations: BMCB, bone metastasis cancer board.